Search

Your search keyword '"Rose Brannon A"' showing total 2 results
Start Over Author "Rose Brannon A" Journal nature medicine
2 results on '"Rose Brannon A"'

1. Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

Author

Jee, Justin, Lebow, Emily S., Yeh, Randy, Das, Jeeban P., Namakydoust, Azadeh, Paik, Paul K., Chaft, Jamie E., Jayakumaran, Gowtham, Rose Brannon, A., Benayed, Ryma, Zehir, Ahmet, Donoghue, Mark, Schultz, Nikolaus, Chakravarty, Debyani, Kundra, Ritika, Madupuri, Ramyasree, Murciano-Goroff, Yonina R., Tu, Hai-Yan, Xu, Chong-Rui, Martinez, Andrés, Wilhelm, Clare, Galle, Jesse, Daly, Bobby, Yu, Helena A., Offin, Michael, Hellmann, Matthew D., Lito, Piro, Arbour, Kathryn C., Zauderer, Marjorie G., Kris, Mark G., Ng, Kenneth K., Eng, Juliana, Preeshagul, Isabel, Victoria Lai, W., Fiore, John J., Iqbal, Afsheen, Molena, Daniela, Rocco, Gaetano, Park, Bernard J., Lim, Lee P., Li, Mark, Tong-Li, Candace, De Silva, Madhawa, Chan, David L., Diakos, Connie I., Itchins, Malinda, Clarke, Stephen, Pavlakis, Nick, Lee, Adrian, Rekhtman, Natasha, Chang, Jason, Travis, William D., Riely, Gregory J., Solit, David B., Gonen, Mithat, Rusch, Valerie W., Rimner, Andreas, Gomez, Daniel, Drilon, Alexander, Scher, Howard I., Shah, Sohrab P., Berger, Michael F., Arcila, Maria E., Ladanyi, Marc, Levine, Ross L., Shen, Ronglai, Razavi, Pedram, Reis-Filho, Jorge S., Jones, David R., Rudin, Charles M., Isbell, James M., and Li, Bob T.

Published
2022
Full Text
View/download PDF

2. Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

Author

Justin Jee, Emily S. Lebow, Randy Yeh, Jeeban P. Das, Azadeh Namakydoust, Paul K. Paik, Jamie E. Chaft, Gowtham Jayakumaran, A. Rose Brannon, Ryma Benayed, Ahmet Zehir, Mark Donoghue, Nikolaus Schultz, Debyani Chakravarty, Ritika Kundra, Ramyasree Madupuri, Yonina R. Murciano-Goroff, Hai-Yan Tu, Chong-Rui Xu, Andrés Martinez, Clare Wilhelm, Jesse Galle, Bobby Daly, Helena A. Yu, Michael Offin, Matthew D. Hellmann, Piro Lito, Kathryn C. Arbour, Marjorie G. Zauderer, Mark G. Kris, Kenneth K. Ng, Juliana Eng, Isabel Preeshagul, W. Victoria Lai, John J. Fiore, Afsheen Iqbal, Daniela Molena, Gaetano Rocco, Bernard J. Park, Lee P. Lim, Mark Li, Candace Tong-Li, Madhawa De Silva, David L. Chan, Connie I. Diakos, Malinda Itchins, Stephen Clarke, Nick Pavlakis, Adrian Lee, Natasha Rekhtman, Jason Chang, William D. Travis, Gregory J. Riely, David B. Solit, Mithat Gonen, Valerie W. Rusch, Andreas Rimner, Daniel Gomez, Alexander Drilon, Howard I. Scher, Sohrab P. Shah, Michael F. Berger, Maria E. Arcila, Marc Ladanyi, Ross L. Levine, Ronglai Shen, Pedram Razavi, Jorge S. Reis-Filho, David R. Jones, Charles M. Rudin, James M. Isbell, and Bob T. Li

Subjects
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mutation, Biomarkers, Tumor, Humans, High-Throughput Nucleotide Sequencing, General Medicine, General Biochemistry, Genetics and Molecular Biology, Circulating Tumor DNA
Abstract

Circulating tumor DNA (ctDNA) sequencing guides therapy decisions but has been studied mostly in small cohorts without sufficient follow-up to determine its influence on overall survival. We prospectively followed an international cohort of 1,127 patients with non-small-cell lung cancer and ctDNA-guided therapy. ctDNA detection was associated with shorter survival (hazard ratio (HR), 2.05; 95% confidence interval (CI), 1.74-2.42; P 0.001) independently of clinicopathologic features and metabolic tumor volume. Among the 722 (64%) patients with detectable ctDNA, 255 (23%) matched to targeted therapy by ctDNA sequencing had longer survival than those not treated with targeted therapy (HR, 0.63; 95% CI, 0.52-0.76; P 0.001). Genomic alterations in ctDNA not detected by time-matched tissue sequencing were found in 25% of the patients. These ctDNA-only alterations disproportionately featured subclonal drivers of resistance, including RICTOR and PIK3CA alterations, and were associated with short survival. Minimally invasive ctDNA profiling can identify heterogeneous drivers not captured in tissue sequencing and expand community access to life-prolonging therapy.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results